| abstract |
A method for treating paroxysmal nocturnal hemoglobinuria with an inhibitor of complement is provided. Eculizumab (a humanized monoclonal antibody to C5 that inhibits terminal complement activation) has shown activity in a preliminary 12-week open label test in a small cohort of paroxysmal nocturnal hemoglobinuria (PNH) patients. Was. In this study, a long-term treatment with eculizumab can reduce intravascular hemolysis or stabilize hemoglobin levels in a multicenter, double-blind, randomized, placebo-controlled, international, phase III study And whether the need for blood transfusion can be reduced and the quality of life can be improved. Eculizumab was found to stabilize hemoglobin levels, reduce the need for transfusion, and improve the quality of life of PNH patients by reducing intravascular hemolysis. [Selection diagram] None |